Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

OICR funding to help six Ontario-based research teams improve the lives of cancer patients

Funding announced today by the Ontario Institute for Cancer Research (OICR) will help six Ontario-based research teams pursue their ultimate goal of improving the lives of people with cancer.

14 Jun 2023

Study illuminates how T cells fight and remember infections

The immune system protects the body from invaders, such as bacteria, viruses, or tumors, with its intricate network of proteins, cells, and organs.

13 Jun 2023

Analyzing the role of LP-284 Hodgkin's lymphoma models and in DNA damage repair

A new research paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, "LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair."

13 Jun 2023

Study raises new hopes for blood cancer patients with an incomplete response to CAR T cell therapy

The aim of immunotherapy strategies is to use cells in the patient's own immune system to destroy tumor cells. CAR T cell therapy is an immunotherapy that is effective in treating blood cancer.

12 Jun 2023

Study offers novel insights into the evolution of multiple myeloma

A new study by researchers at The University of Texas MD Anderson Cancer Center highlights novel insights into the evolution of multiple myeloma from precursor disease, which may help better identify patients likely to progress and develop new interventions.

12 Jun 2023

Pandemic restrictions associated with a significant drop in cancer diagnoses

Pandemic restrictions corresponded with a significant drop in diagnoses of breast, colorectal and prostate cancers as well as melanoma, according to a new Alberta study published in CMAJ (Canadian Medical Association Journal)

12 Jun 2023

Phase III ZUMA-7 trial: Patients with high-risk large B-cell lymphoma lived longer with axi-cel

Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival when treated with the chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel (axi-cel) when compared to the current standard-of-care chemoimmunotherapy, according to results of the Phase III ZUMA-7 trial reported by researchers from The University of Texas MD Anderson Cancer Center.

5 Jun 2023

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

At the 2023 American Society for Clinical Oncology Annual Meeting—to be held June 2-6 in Chicago, Illinois—Fred Hutchinson Cancer Center experts will present research spanning survivorship, advances in treatments and clinical trials, how access to cancer care affects outcomes, integrative medicine and more.

5 Jun 2023

SWOG Cancer Research Network clinical trial reveals potential new therapy for Stage 3 or 4 classic Hodgkin lymphoma

A Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly lower risk of their cancer getting worse than patients treated with brentuximab vedotin, a monoclonal antibody, and AVD (BV-AVD) a year after starting treatment.

4 Jun 2023

New data guides treatment choices for patients with r/r lymphoma during pregnancy

Today, Blood Advances published a study revealing that patients with relapsed/refractory (r/r) lymphoma during pregnancy experienced a progression-free survival rate of 24% and an overall survival rate of 83%.

1 Jun 2023

Novel treatment targets against natural killer/T-cell lymphoma identified

A team of researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore has discovered that a transcription factor, TOX2, was aberrantly increased in patients with Natural killer/T-cell lymphoma (NKTL).

29 May 2023

2023 PCRF grant recipients announced for exploring new, safer treatments for pediatric cancers

The Pediatric Cancer Research Foundation, a nonproﬁt focused on transforming pediatric cancer care by accelerating research breakthroughs, today announced the 19 recipients of its 2023 research grants.

26 May 2023

Young adult cancer survivors at higher risk of heart failure when treated with anthracyclines

Imagine surviving cancer only to learn the drug that saved your life has introduced a completely different health risk: heart failure.

16 May 2023

Cancer patients can initiate SARS-CoV-2 vaccination three months after bone marrow transplant

Patients with cancer whose immune systems are being supported or rebuilt by bone marrow transplantation should begin receiving vaccines for protection against SARS-CoV-2 three months post-transplant, according to a large, prospective, observational study led collaboratively by the Center for International Blood and Marrow Transplant Research, the Blood & Marrow Transplant Clinical Trials Network and Fred Hutchinson Cancer Center.

16 May 2023

Break Through Cancer funds AML research at MD Anderson

The University of Texas MD Anderson Cancer Center was awarded more than $5.7 million in grants from Break Through Cancer to support collaborative research teams working to discover novel molecular targets to eradicate minimal residual disease in acute myeloid leukemia (AML) and to treat clonal hematopoiesis, a precursor to AML.

16 May 2023

Young Geneva researcher wins SAKK Trial Network Award for clinical research on lymphoma

A young researcher from the Geneva University Hospital (HUG) and the University of Geneva (UNIGE), Dr Noémie Lang, wins the prestigious Swiss Group for Clinical Cancer Research (SAKK) Trial Network Award, with the intent to carry out a study evaluating early detection of central nervous system involvement in lymphomas.

12 May 2023

Combination treatment shows promise for aggressive subtype of non-Hodgkin lymphoma

Nearly 90 percent of patients with an aggressive subtype of non-Hodgkin lymphoma had their cancer go into remission in a small phase 2 clinical trial testing a treatment aimed at making chemotherapy more effective, according to Weill Cornell Medicine and NewYork-Presbyterian investigators.

5 May 2023

Lymphoma News and Research

Further Reading

OICR funding to help six Ontario-based research teams improve the lives of cancer patients

Study illuminates how T cells fight and remember infections

Analyzing the role of LP-284 Hodgkin's lymphoma models and in DNA damage repair

Study raises new hopes for blood cancer patients with an incomplete response to CAR T cell therapy

Study offers novel insights into the evolution of multiple myeloma

Pandemic restrictions associated with a significant drop in cancer diagnoses

Phase III ZUMA-7 trial: Patients with high-risk large B-cell lymphoma lived longer with axi-cel

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

SWOG Cancer Research Network clinical trial reveals potential new therapy for Stage 3 or 4 classic Hodgkin lymphoma

New data guides treatment choices for patients with r/r lymphoma during pregnancy

Novel treatment targets against natural killer/T-cell lymphoma identified

2023 PCRF grant recipients announced for exploring new, safer treatments for pediatric cancers

Young adult cancer survivors at higher risk of heart failure when treated with anthracyclines

Cancer patients can initiate SARS-CoV-2 vaccination three months after bone marrow transplant

Break Through Cancer funds AML research at MD Anderson

Young Geneva researcher wins SAKK Trial Network Award for clinical research on lymphoma

Combination treatment shows promise for aggressive subtype of non-Hodgkin lymphoma

Light or moderate exercise can improve the prognosis of cancer

Montana considers requiring insurance to cover fertility preservation for cancer patients

How to increase your social network as you age

Everything you should know about lymphoma eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News